Unknown

Dataset Information

0

Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.


ABSTRACT:

Background

Intranasal delivery of vaccines directed against respiratory pathogens is an attractive alternative to parenteral administration. However, using this delivery route for inactivated vaccines usually requires the use of potent mucosal adjuvants, and no such adjuvant has yet been approved for human use.

Methodology/principal findings

We have developed a live attenuated Bordetella pertussis vaccine, called BPZE1, and show here that it can be used to present the universal influenza virus epitope M2e to the mouse respiratory tract to prime for protective immunity against viral challenge. Three copies of M2e were genetically fused to the N-terminal domain of filamentous hemagglutinin (FHA) and produced in recombinant BPZE1 derivatives in the presence or absence of endogenous full-length FHA. Only in the absence of FHA intranasal administration of the recombinant BPZE1 derivative induced antibody responses to M2e and effectively primed BALB/c mice for protection against influenza virus-induced mortality and reduced the viral load after challenge. Strong M2e-specific antibody responses and protection were observed after a single nasal administration with the recombinant BPZE1 derivative, followed by a single administration of M2e linked to a virus-like particle without adjuvant, whereas priming alone with the vaccine strain did not protect.

Conclusions/significance

Using recombinant FHA-3M2e-producing BPZE1 derivatives for priming and the universal influenza M2e peptide linked to virus-like particles for boosting may constitute a promising approach for needle-free and adjuvant-free nasal vaccination against influenza.

SUBMITTER: Kammoun H 

PROVIDER: S-EPMC3602086 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.

Kammoun Hana H   Roux Xavier X   Raze Dominique D   Debrie Anne-Sophie AS   De Filette Marina M   Ysenbaert Tine T   Mielcarek Nathalie N   Saelens Xavier X   Fiers Walter W   Locht Camille C  

PloS one 20130319 3


<h4>Background</h4>Intranasal delivery of vaccines directed against respiratory pathogens is an attractive alternative to parenteral administration. However, using this delivery route for inactivated vaccines usually requires the use of potent mucosal adjuvants, and no such adjuvant has yet been approved for human use.<h4>Methodology/principal findings</h4>We have developed a live attenuated Bordetella pertussis vaccine, called BPZE1, and show here that it can be used to present the universal in  ...[more]

Similar Datasets

| S-EPMC8310119 | biostudies-literature
| S-EPMC9060463 | biostudies-literature
| S-EPMC4760421 | biostudies-literature
| S-EPMC7912525 | biostudies-literature
| S-EPMC5483252 | biostudies-other
| S-EPMC4634119 | biostudies-other
| S-EPMC3072404 | biostudies-literature
| S-EPMC4494237 | biostudies-literature
2021-01-21 | E-MTAB-9385 | biostudies-arrayexpress
| S-EPMC9243060 | biostudies-literature